Efficiency of Tranexamic Acid in Management of Surgical Orthopedic Bleeding in Patients with Haemophilia

OANA VIOLA BADULESCU1, RAZVAN TUDOR2*, WILHELM FRIEDL3, MIHAELA BLAJ4, PAUL DAN SIRBU1

1 Grigore T. Popa University of Medicine and Pharmacy, Iasi, Faculty of Medicine, Department of Pathophysiology, Morpho-Functional Sciences (II), 16 Universitatii Str., 700115, Iasi, Romania
2 Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, Faculty of Medicine, Department of Orthopedics and Traumatology, Surgical Sciences (II), 16 Universitatii Str., Iasi, Romania
3 Aschaffenburg Hospital, Department of Orthopedics and Traumatology, Germany
4 Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, Faculty of Medicine, Department of Anesthesia and Intensive Care, Surgical Sciences (I), 16 Universitatii Str., Iasi, Romania

Haemophilia is an inherited bleeding disorder (gonosomal recessive, related to chromosome X, with transmission from carrying women to male descendents) characterised from the clinic point of view by important bleeding, secondary to some minimum and biologic traumas by deficiency of trombo-plastino-formation, consecutive to either a deficit of factor VIII (haemophilia A), or the factor IX (haemophilia B). The most characteristic manifestation of hemophilia is intra-articular – hemarthrosis. Its repetitive character leads to irreversible lesions of the articular structures, inducing lesions of the synovium with degenerative effects over the articular cartilage and destructive effects for the subchondral bone tissue. In time, these lesions require orthopaedic surgery to improve the locomotor activity. Managing an efficient hemostasis is vital during surgery, due to high risk of bleeding triggered by coagulopathy and surgery. Numerous studies carried out underlined the efficiency of the tranexamic acid (TXA) in reducing bleeding, in different surgery branches, by inhibiting the enzymatic degradation of fibrin. In orthopaedic surgery, the tranexamic acid is frequently used in case of hip and knee arthroplasties, reducing the bleeding and blood transfusion necessary to the treatment of posthaemorrhagic anemia. This paper wants to assess the efficiency of the tranexamic acid in realization of hemostasis to another category of patients, haemophiliac patients with indication of total hip and knee endoprosthesis.

Keywords: haemophilia, total hip replacement, total knee replacement, tranexamic acid

Haemophilia is a mostly inherited coagulopathy due to the factor VIII coagulation deficiency (haemophilia A) or factor IX coagulation deficiency (haemophilia B). Haemophilia affects about 600,000 people worldwide, 20% of which develop antibodies for factor coagulation deficiency. From the clinic point of view, it is characterised by bleeding events of different intensity, depending on how severe the disease is or the intensity of the trauma the patient is exposed to. The patients with severe form of disease (VIII factor coagulation is under 1%) can present spontaneous bleeding, in most cases in joints (hemarthrosis) or muscles (hematomas), some even with vital risk in the absence of treatment of substitution with antihemophilic factor. The severity of bleeding in haemophilia is commonly related to the level of coagulation factor, as it is mentioned in table 1 [1-3].

The indications of the orthopaedic surgery are initially acute, then chronic with degenerative effects on the articular cartilage by chondrocyte apoptosis, and with destructive effects on the subchondral bone tissue, in time occurring the main chronic complication: haemophilia arthropathy [3-5].

The hemophilia arthropathy can affect one or more joints, mainly in the knee, hip, ankle and elbow, in 90% of haemophilic patients [5]. At the same time, it generates increased articular instability and reduced mobility, until total ankylosis, with invalidating potential and decrease of patient’s life quality. From the orthopaedic perspective, the treatment of hemophilia arthropathy can be done by conservative methods or surgery. The conservative methods are orthoses, joint evacuatory puncture, intra-articular injection of anti-inflammatory drugs, intra-articular corticosteroid therapy, injections of hyaluronic acid and chondroitin sulfate, radiosynoviorthesis, gradual corrective straightening of ankylosis in flexion. A complex multidisciplinary team is required, made of a hematologist, an orthopedic surgeon, medical restoration physicians, physical therapist for optimal results. These orthopaedic procedures must be carried out in hospitals by experimented teams [5-7].

Hemophilic patient’s preoperative balance presents some particularities (table 2).

The main objectives of the multi-disciplinary team are improving the functionality and the life quality of the haemophilic patient. The indications of the orthopaedic surgery are represented in table 3 [4].

Table 1

<table>
<thead>
<tr>
<th>Severity</th>
<th>Clotting factor level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe</td>
<td>&lt;1% of normal</td>
</tr>
<tr>
<td>Moderate</td>
<td>1 to 5% of normal</td>
</tr>
<tr>
<td>Mild</td>
<td>5 to &lt;40% of normal</td>
</tr>
</tbody>
</table>

* email: rc_tudor@yahoo.com
In cases of severe haemophilic arthropathy, it is approached through basic surgery, represented by total arthroplasty, radiosynovectomy, chemical synovectomy, arthroscopic synovectomy and arthrodesis [5,6,8,9].

Severe hip arthropathy is much less frequent than that of the knee, elbow or ankle. The radiologic image can have the aspect of a juvenile arthritis or coxarthrosis. Increased pressure in the intra-articular space can determine the appearance of the aseptic necrosis of femoral tip. In patients with important destruction of coxo-femoral articulations, total hip arthroplasty was very efficient, with significant improvement of articular amplitude. Knee arthropathy is the most frequent cause of pain and invalidity in patients with haemophilia [5,9,10].

Indications for arthroplasty are represented by: articular pain and invalidity, which does not respond to conservative treatment, as well as advanced radiologic modifications. The objectives of this surgery consist in diminishing pain, improving articular amplitude and correcting deformation [3-6].

Total endoprosthesis, in their cemented version, are indicated in major articular destructions, which lead to important functional deficit. Indication of total endoprosthesis remains to be evaluated from the point of view of the remote prognostic. The main risks consist in infection and aseptic enlargement of bone structures, which influence the stability of the endoprosthesis. The major indication of endoprosthesis aims mainly the hip and knee joint, and it is done with prudence at young ages. They are currently improved a lot, both from the point of view of the surgery technique and the material of the prostheses, so that the indications of usage have extended when it comes to the age and articulations targeted (including ankle articulations) [3,5,8,11].

Post-surgery bleeding is the main complication that can appear in haemophilic patient who underwent total arthroplasty [5,11].

More observational studies associated the post-surgery blood transfusion with a longer hospitalization period, higher costs, frequent infections, and mortality in some cases. [4-6,8,9] Taking into consideration the major risk of bleeding in the haemophilic patient, mainly by coagulopathy but also the type of surgery, most endoprostheses are scheduled to assure the necessary quantity of coagulation factor for substitutive treatment, and another haemostatic adjuvant, such as tranexamic acid as an antifibrinolytic agent [5,8,10,12-17].

Currently, the standard protocols of treating the patient plead for the necessity of using a haemostatic product that, once administered, can perform an efficient haemostasis. In this sense, anti-fibrinolytic drugs such as tranexamic acid, researched in numerous studies, have proved their safety and efficiency in orthopaedic surgery [5,12-17].

The tranexamic acid was initially used about 40 years ago in cardio-thorax surgery, in controlling gynecological bleeding and in bleedings secondary to major traumas. Apart from its use in surgery (orthopaedic, cardio-thorax surgery, gynaecology, gastroenterology and hepatology, urology, ENT), efficiency of tranexamic acid was also studied in some hematologic pathologies such as deficiency of factor von Willlebrand, in hemophilia or thrombocytopenia [13]. It is frequently and successfully used in orthopaedic to reduce the perioperative bleeding events, especially in patients with total hip or knee arthroplasty [13,16,17].

**Tranexamic acid**

The tranexamic acid, discovered in 1960, is a synthetic derivative of lysine with antifibrinolytic action; it prevents

---

**Table 2**

<table>
<thead>
<tr>
<th>Preoperative balance</th>
<th>Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity and type of haemophilia</td>
<td>- estimating the substitutive treatment; - requirement of factor concentrate being dependent also on the scale of intervention and restoration</td>
</tr>
<tr>
<td>Determination of the presence of circulating inhibitors</td>
<td>• Crucial to avoid some potentially lethal complications; • Even low level of inhibitors can increase spectacularly after giving high doses of factors immediately before and after surgery.</td>
</tr>
<tr>
<td>Exploring the viral status</td>
<td>It is necessary to repeat the serologic tests to find any infection with VHB, VHC, HIV before surgery, if they were not done during the last 3 months (active hepatitis is a contraindication for surgery)</td>
</tr>
<tr>
<td>Complete clinic and imagistic evaluation</td>
<td>• in view of carrying out multiple correcting surgeries, so that the same consumption of coagulation factor could solve more orthopaedic problems.</td>
</tr>
</tbody>
</table>

**Table 3**

<table>
<thead>
<tr>
<th>Indications of orthopaedic surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. chronic sinovitis – cannot be controlled in a conservative way, with recommendation of synovectomy</td>
</tr>
<tr>
<td>b. bone and joint deformations, muscular contractions with recommendation of osteotomy and arthroscopic arthrolysis</td>
</tr>
<tr>
<td>c. degenerative joint modifications with recommendation of prosthesis or arthrodesis</td>
</tr>
<tr>
<td>d. haemophilic pseudo-tumours with recommendation of excision</td>
</tr>
<tr>
<td>e. open fractures</td>
</tr>
<tr>
<td>f. invalidating pain</td>
</tr>
</tbody>
</table>

---

**Table 2**

| HEMOPHILIC PATIENT'S PREOPERATIVE BALANCE |

---

**Table 3**

| INDICATIONS OF ORTHOPAEDIC SURGERY - ADAPTED FROM [4] |

---

Post-surgery bleeding is the main complication that can appear in haemophilic patient who underwent total arthroplasty [5,11].

More observational studies associated the post-surgery blood transfusion with a longer hospitalization period, higher costs, frequent infections, and mortality in some cases. [4-6,8,9] Taking into consideration the major risk of bleeding in the haemophilic patient, mainly by coagulopathy but also the type of surgery, most endoprostheses are scheduled to assure the necessary quantity of coagulation factor for substitutive treatment, and another haemostatic adjuvant, such as tranexamic acid as an antifibrinolytic agent [5,8,10,12-17].

Currently, the standard protocols of treating the patient plead for the necessity of using a haemostatic product that, once administered, can perform an efficient haemostasis. In this sense, anti-fibrinolytic drugs such as tranexamic acid, researched in numerous studies, have proved their safety and efficiency in orthopaedic surgery [5,12-17].

The tranexamic acid was initially used about 40 years ago in cardio-thorax surgery, in controlling gynecological bleeding and in bleedings secondary to major traumas. Apart from its use in surgery (orthopaedic, cardio-thorax surgery, gynaecology, gastroenterology and hepatology, urology, ENT), efficiency of tranexamic acid was also studied in some hematologic pathologies such as deficiency of factor von Willlebrand, in hemophilia or thrombocytopenia [13]. It is frequently and successfully used in orthopaedic to reduce the perioperative bleeding events, especially in patients with total hip or knee arthroplasty [13,16,17].

**Tranexamic acid**

The tranexamic acid, discovered in 1960, is a synthetic derivative of lysine with antifibrinolytic action; it prevents
replacement therapy, an anticoagulant treatment with low
(fig. 3). Due to the normalized coagulation profile after the
400 mL, similar to that of a patient without haemophilia
Bleeding after surgery was minimal in both cases, of about
haemoglobin did not impose transfusion treatment.
was very good; paraclinically, the decrease of the level of
interfered were carefully monitored. Haemostasis was
complications in the orthopaedic field that could have
parameters, transfusion requirements, and any
hemoglobin and hematocrit, coagulation profile
orthopaedic surgery, as well as after surgery, the level of
6-8 h according to the protocol mentioned. During the
same time, tranexamic acid 25 mg/Kg i.v. was given every
157.213g/mol (fig. 2). In the haemophilic patients,
administration is on short term (2-8 days) to reduce or
prevent minor bleeding (for example tooth extraction), but
it can be extended to 14 days according to the protocols in
case of hip or knee arthroplasty [22].

Experimental part
Material and method
Two patients with severe form of haemophilia A were
evaluated from the orthopaedic point of view (factor VIII
< 1%) with present inhibitors, with chronic haemophilic
arthropathy algically and functionally decompensated, with
severe motor deficit, who presented indication of
degradation of fibrin, by reversible inhibition of
plasminogen. This mechanism prevents the conversion of
plasminogen into plasmin and to exercise its fibrinolytic
action (fig.1). The halving period of the tranexamic acid is
2 h, and its excretion is through kidneys [13,18-21].
From the chemical point of view, it is a trans-4-
aminomethylcyclohexancarboxylic acid, corresponding to
the chemical formula \(C_8H_{15}NO_2\) with molecular mass of
175.213g/mol (fig. 2). In the haemophilic patients,
administration of tranexamic acid, was also supported by
Sukeik et al., in their study [23].

The absence of secondary thromboembolic events, after
administration of tranexamic acid in association with the substitutive factor
hypothesis also in the case of the haemophilic patients,
out in our service of orthopaedics have confirmed this
results underlined a reduction of the postoperative bleeding
phenomena and, implicitly, the necessary quantity of
transfusion for both types of arthroplasty, without
increasing the rate of thromboembolic complications. [20]
The tranexamic acid in the standard haemostatic protocol in the patients
where it was practised total hip or knee arthroplasty; the
results underlined a reduction of the postoperative bleeding
phenomena, bleeding being lower in patients with higher
dose of 10-15 mg/kg i.v., underlining the direct proportion
of coagulation. Also in this sense, Benone et al. concluded
these studies showed that the tranexamic acid proved to
be efficient and safe in orthopaedic surgery [12-
18,20,21,23-26]. The two cases of endoprosthesis carried
out in our service of orthopaedics have confirmed this
hypothesis also in the case of the haemophilic patients,
who were administered in the hemostatic protocol
trianexamic acid in association with the substitutive factor
coaulation. Also in this sense, Benone et al. concluded
that the minimum concentration for an efficient therapeutic
level is 10 mg/ Kg body, repeated every 8 h [27].

In a meta-analysis, Sukeik et al. [23] identified at 11
eligible studies with 505 patients undergoing endo-
prosthesis, where the tranexamic acid was used to carry
out hemostasis, and two years later, Zhou et al. [29] added
another 8 studies, including 525 patients who underwent
the same type of surgery and were administered the same
haemostatic. The tranexamic acid was administered in
dose of 10-15 mg/kg i.v., underlining the direct proportion
between the doses administrated and the hemorrhagic
phenomena, bleeding being lower in patients with higher
administrated doses [28].

Also in order to evaluate the efficiency of the tranexamic acid, Tan et al. carried out a meta-analysis on 1114 patients
and noticed that its administration reduces post-surgery bleeding and the necessary transfusion amount; also, in the lot of patients studied, there were not thromboembolic events or other side effects of the tranexamic acid treatment [29].

Yang et al. studied the relation between the tranexamic acid and aPTT, but without underlining the relation in this sense, because the aPTT value is not influenced by the use of tranexamic acid [14].

According to the research, the i.v. administration of the tranexamic acid seems to be the most efficient method of administration for the tranexamic acid, because it can enter relatively fast in large joints. In a study of meta-analysis it was proved that one topic administration is much inferior to the i.v. one, in total knee arthroplasty, and there is a risk of severe bleeding that imposes secondary transfusion treatment with red blood cells [13,30,31]. In the haemophilic patients with endoprosthesis in our hospital, the i.v. administration of the tranexamic acid has proved to be efficient, the post-surgery values of the haemoglobin not imposing transfusion treatment.

Conclusions

Hemophilia is a chronic hereditary coagulopathy that requires treatment of substitution with lifelong haemophilic factor. The main chronic complication of this disease, the haemophilic arthropathy, causes disabling sequelae, requiring surgical orthopaedic treatment.

In orthopaedic surgery of the haemophilic patient, the tranexamic acid, as antifibrinolytic agent, has proved its efficiency in reducing the bleeding events and the necessity of transfusion in patients with indication of total hip or knee arthroplasty, without generating thromboembolic events, fact confirmed also by the two cases of endoprosthesis in our hospital.

All these effects of the tranexamic acid improve the patient's safety and decrease the costs related to the medical care.

References

22. P. L. F. GIANGRANDE et al., Consensus protocol for the use of recombinant activated factor VII (epotacog alfa (activated); NovoSeven) in elective orthopaedic surgery in haemophilic patients with inhibitors, Haemophilia (2009), 15, 501-508.

Manuscript received: 8.09.2016

630

http://www.revistadechimie.ro

REV.CHIM.(Bucharest) ♦ 68 ♦ No. 3 ♦ 2017